Nutranomics, Inc.

Nutranomics, Inc. engages in the research, development, and sale of nutritional food products. It offers approximately 480 nutritional supplements, including formulating vitamin, mineral, herbal, and probiotic supplements. The company provides Nutritional Blood Analysis, a tool to examine the customer's blood cells on a video monitor, live, in real time; and the patented Assimilation Enhancing System that improves the absorption of nutrients. In addition, it offers educational services, including various types of analyses, trainings, certifications, and group presentations to individuals and industry professionals. The company distributes its products through sales representatives throughout North America and Asia, as well as through retail stores. Nutranomics, Inc. has a strategic partnership with Terra-Formance, LLC. The company was founded in 1995 and is headquartered in Salt Lake City, Utah.

Nutranomics, Inc. trades as NNRX on OTC. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in USD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $2.85M of revenue and -$6.63M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Nutranomics, Inc. can be compared against peers such as Acura Pharmaceuticals, Inc., Amexdrug Corporation, Endonovo Therapeutics, Inc., Filament Health Corp., Medical Imaging Corp., Wayland Group Corp..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $816,232, beta of -0.15, and return on equity of +62.8%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

NNRX currently shows total debt of $14.82M and beta of -0.15. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.nutranomics.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.